Biocon stock
BIOCON.NSNSEBiocon Limited, HealthcareISIN INE376G01013
41Score 41 out of 100, Weak
Price and trend
52 / 100
Price history
−8.6% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 4.9% below it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Overheated: the price has risen very quickly lately (RSI 83).
The price is 16% below its 52-week high. Largest decline in 20 years: 72% (November 2007 to November 2008).
Chart figures for advanced users
- SMA 50$3.90
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$4.15
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)83
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$3.44
- The lowest closing price of the last twelve months.
- Resistance$4.68
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Biocon Limited belongs to the Biotechnology industry (India) and, with a market value of $6.42B, is number 61 of 289 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $1.8B (up 10.9% year on year) and earnings of $40.98M (down 61.9%).
- For fiscal 2027, analysts expect on average revenue of $2.04B (up 13.5%) and adjusted earnings per share of $0.07 (up 102%).
Show more
- MEQIRI Score 41 out of 100 (Weak): rank 520 of 702 in Healthcare, median 53.
- The P/E is 133.7 because earnings over the last twelve months collapsed; on the expected earnings of the next twelve months it is 40.2 (Biotechnology median 45.8). The P/E therefore does not count in the score.
- Our model puts fair value at $1.05, with the price 275% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Analysts expect strong earnings growthUp 44.7% a year through 2029 (estimates from 13 analysts).Growth 50
- Consistently profitableProfit in all 10 fiscal years from 2017 to 2026.
Weaknesses
- Above fair valuePrice 275% above the fair value of $1.05.Valuation 15
- Margin fallingOperating margin 8.9%, average of the prior years 30.9% (to 2025).Profitability 29
- Interest barely coveredOperating profit covers interest only 1.5 times.Stability 60
The score is held back by capital allocation and valuation.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Significantly overvaluedIn our model the price counts as cheap below $0.81 and expensive above $1.50 (uncertainty medium, based on the price swings of the past year).
Calculated with a cost of equity of 17.1%. At 18.1% the fair value would be $0.95, at 16.1% it would be $1.18.
Valuation metrics
From the cash-flow model alone; after a one-off collapse in earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 5.9% on the twelve months before. Revenue has grown strongly since 2007, at around 17% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 35%, operating 9%, net 2%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 4 Feb 2027in 83 days
- Last reported
- 4 Nov 2026EPS reported $0.00 (expected $0.01)below expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 6.4% since 1 Nov 2026. Falling estimates often precede bad news.
- Earnings per share
- $0.07−6.4%
- Revenue
- $2.04B−0.9%
- Earnings per share
- $0.12−2.9%
- Revenue
- $2.34B−1.0%
MEQIRI has stored the estimates since 1 Nov 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Biocon
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 41
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Kodiak SciencesKOD $6.8B43
- Belite BioBLTE $6.76B45
- Arrowhead PharmaceuticalsARWR $6.66B30
- ImmunityBioIBRX $6.46B37
- Samsung Epis Holdings0126Z0.KS $6.4B41
- Ligand PharmaceuticalsLGND $6.33B60
- CG OncologyCGON $6.27B41
- Hangzhou Tigermed Consulting300347.SZ $6.12B46
ETFs that hold Biocon
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares MSCI EM Small Cap UCITS ETFEUNI | 0.16% | 0.74% | €279.38M |
| Vanguard FTSE Emerging Markets UCITS ETF (USD) AccumulatingVFEA | 0.03% | 0.17% | €5.24B |
| iShares MSCI EM IMI Screened UCITS ETF USD (Acc)AYEM | 0.02% | 0.18% | €5.26B |
Show 5 more
| iShares Core MSCI EM IMI UCITS ETFIS3N | 0.02% | 0.18% | €37.98B |
| Vanguard FTSE All-World UCITS ETF (USD) AccumulatingVWCE | 0.00% | 0.14% | €79.59B |
| Vanguard ESG Global All Cap UCITS ETF (USD) AccumulatingV3AA | 0.00% | 0.24% | €1.69B |
| Amundi Prime All Country World UCITS ETF AccWEBN | 0.00% | 0.07% | €8.95B |
| Vanguard FTSE Global All-Cap UCITS ETF Accum USDVGLA | 0.00% | 0.07% | €3.9B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ₹94.0836)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jul 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.